Company intelligence / Profile preview

Promosome

New York City, New York, USA

Ownership: Private
Development stage: Other

Overview

Promosome has developed proprietary technology for reengineering messenger RNA (mRNA) to enhance protein expression through modifications. The company has been involved in patent litigation related to its mRNA technology, including a lawsuit against Moderna and Pfizer for alleged patent infringement on COVID-19 vaccines[6].

Modalities: mRNA-based drugs
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Promosome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promosome.

Explore the full profile